franckreporter/iStock via Getty Images
- Seres Therapeutics (MCRB) +11% announces confirmatory results from investigational microbiome therapeutic SER-109 ECOSPOR IV open-label study in recurrent C. difficile infection.
- Kohl's (KSS) +10% after entering exclusive talks for $60/share sale to Franchise Group.
- GitLab (GTLB) +9% on Q1 earning beat.
- Dave & Buster's (PLAY) +5% on Q1 results.
- Context Therapeutics (CNTX) +5%.
- BuzzFeed (BZFD) +5% amid lockup expiration.
- Mirati Therapeutics (MRTX) +5%.